Lupin has received the Establishment Inspection Report (EIR) after closure of the United States Food and Drug Administration (USFDA) inspection of its Nagpur, India facility. The inspection for the facility was carried out by the USFDA between January 6, 2020 and January 10, 2020.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.